Background. Percutaneous ablation of accessory pathways with the use of a defibrillator can be accomplished with high-energy direct-current (DC) shocks of 150-400 J, but complications include cardiac tamponade and sudden cardiac death, mostly resulting from significant electrical arcing and barotrauma. A new low-energy DC power source with a brief time-constant capacitive discharge delivers shocks of 2-40 J and eliminates or greatly reduces arcing. This report describes our initial experience with this device in 60 consecutive patients (mean age, 34 years; range, 9-67 years) with Wolff-Parkinson-White syndrome. Accessory pathways were located in the left free wall in 36 patients, in the right free wall in two, were posteroseptal in 18, and anteroseptal in four. Most patients (77%) had their initial diagnostic electrophysiological study and catheter ablation during the same session.
Methods

Patients
Between May 1989 and March 1991, 60 consecutive patients with the Wolff-Parkinson-White syndrome underwent low-energy DC ablation at the Montreal Heart Institute. There were 34 men and 26 women; mean age was 34±14 years (range, 9-67 years). Associated congenital heart disease was present in three patients (corrected L-transposition of the great vessels in one and Ebstein's anomaly in the other two). Surgical ablation of a left free wall accessory pathway had previously been unsuccessful in two patients, and highenergy DC ablation had failed in three others: one with the permanent form of junctional reciprocating tachycardia, one with a left free wall, and another with a right free wall accessory pathway.
All patients had symptomatic tachycardias with a mean duration of 13+8 years. Patients had been refractory to a mean of 3±2 (range, 0-6) antiarrhythmic drugs, including amiodarone in eight cases (13%). Orthodromic reciprocating tachycardia was documented in 51 patients, and atrial fibrillation was present in nine, degenerating into ventricular fibrillation in one of them.
Catheter Ablation
The study protocol was approved by the Institutional Review Board of the Montreal Heart Institute. Written consent was obtained from all patients. In 46 patients (77%), both the diagnostic electrophysiological study and the catheter ablation were performed in the same session. Catheter ablation was performed with the patient fasting, after discontinuing antiarrhythmic drugs for at least five half-lives. Electrode catheters were introduced from the femoral veins and the right internal jugular vein, or when technically difficult, by the left subclavian vein. Arterial catheters were introduced via the right or left femoral artery, or into the radial artery when only arterial pressure recording was necessary. The venous catheters were positioned in the high right atrium, His bundle region, right ventricle, and coronary sinus. Three approaches were used in patients with left free wall accessory pathways: In one patient, mapping and ablation were performed via a patent foramen ovale; in seven others, the ablation was performed directly within the coronary sinus without complications; and in 28, the catheter introduced from the femoral artery was positioned in the left ventricle and left atrium via a retrograde aortic approach for mapping and ablation in the region of the mitral annulus.
Electrocardiographic leads I, aVF, and V, and the intracardiac electrograms were amplified (Electronicsfor-Medicine VR12, Pleasantville, N.Y.) and recorded (Siemens-Elena Mingograf 7 jet ink recorder, Solera, Sweden) at paper speeds of 25, 100, and 250 mm/sec.
Pacing was performed with a programmable stimulator (Bloom Associates, Naberth, Pa.). The duration of the pacing stimuli was 2 msec, and the current strength was twice that of late diastolic threshold.
Cardiac Mapping
Accessory pathways were localized using previously published criteria.19 The coronary sinus was mapped with both unipolar and bipolar recordings, usually using a 6F 
Catheter Ablation Protocol
Continuous intravenous heparin (bolus of 2,500 units followed by 1,000 units/hr in adults; bolus of 1,000 units followed by 500 units/hr in children) was started before ablation. Patients were anesthetized with various drugs, including midazolam, fentanyl, nalbufine, thiopental, propofol, or ketamine. Test shocks of 2-10 J were delivered. If they were successful in eliminating conduction through the accessory AV connection, four to six successive shocks of 15-30 J (aiming for 1,500-2,000 V per shock) were given to promote tissue damage. Patients were then observed in the electrophysiological laboratory for approximately 1 hour. If accessory pathway conduction resumed, mapping was again performed and another series of shocks was given. The maximum duration of a session was limited to 6-7 hours. After ablation, quadripolar catheter with 1-cm interspace between elecall patients were returned to the arrhythmia unit, where they were continuously monitored and treated with intravenous heparin (1,000 units/hr) until hospital discharge. Serial creatine kinase MB isoenzyme measurements were obtained; 48 patients (80%) also had a two-dimensional echocardiogram before hospital discharge. A technetium pyrophosphate scintigram, usually with tomographic imaging, was performed 2-4 days after ablation in 51 patients.
Early and Late Follow-up Electrophysiological Studies
An electrophysiological study was performed 2-7 days after ablation; when reciprocating tachycardia could be induced, catheter ablation was repeated. Patients received oral coumadin for 3 months and were reevaluated in the arrhythmic clinic. Late electrophysiological studies were performed between April and June 1991, a mean of 9±5 months (range, 3-23 months) after ablation. During this study, conduction times and refractory periods of the atrium and AV node were determined. During pacing of the right ventricular apex at 400 msec, up to two ventricular extrastimuli were given to assess inducibility of ventricular tachycardia. If patients demonstrated retrograde conduction during ventricular pacing, a 12-mg bolus of intravenous adenosine followed by 10 ml of saline was given during ventricular pacing with 1: 1 retrograde (VA) conduction. Retrograde block after adenosine and retrograde decremental conduction were used to confirm conduction through the AV node.
Statistical Analyses
All statistical comparisons were performed using an unpaired two-tailed Student's t test. A probability value of less than 0.05 was considered significant.
Results
The accessory pathway was located in the left free wall in 36 patients, in the right free wall in two, was posteroseptal in 18, and anteroseptal in four. Manifest preexcitation was present in 40 patients (67%), and a concealed accessory pathway was present in 20 (33%).
Mean anterograde and retrograde effective refractory periods were 278±+82 and 263+±43 msec, respectively.
Four patients had another accessory pathway documented during electrophysiological testing or concealed until after ablation: both patients with Ebstein's anomaly had a posteroseptal and a right free wall accessory pathway, one patient had a left free wall and a posteroseptal accessory pathway, and the fourth had a posteroseptal and a right free wall accessory pathway. During mapping, the mean cycle length and the mean shortest VA interval during orthodromic reciprocating tachycardia were 336+±50 and 93+±25 msec, respectively. The mean cumulative energy per patient was 312±284 J.
Success
Ablation was successful in 35 patients (97%) with a left free wall accessory pathway, in 15 (83%) with a posteroseptal accessory pathway, in both patients with a right free wall accessory pathway, and in three patients (75%) with an anteroseptal accessory pathway. Therefore, the overall success rate was 92% (55 of 60 patients). The only patient with a left free wall accessory pathway for whom ablation failed had the procedure stopped because of cardiac tamponade (see below). Before ablation in one patient with a concealed posteroseptal accessory pathway, orthodromic reciprocating tachycardia could only be induced with an infusion of isoproterenol. After ablation, orthodromic reciprocating tachycardia could still be induced after isoproterenol, and the procedure was stopped. One patient with a concealed anteroseptal accessory pathway had transient AV block with shocks of 5-15 J; the procedure was terminated, and he was treated medically with sotalol. In both patients with Ebstein's anomaly, preexcitation was abolished transiently (up to 48 hours) but recurred permanently in one patient and is intermittent in the other patient. In these patients, difficulties in mapping and catheter stability occur because of downward displacement of the tricuspid valve and tricuspid regurgitation. An electrode catheter inserted into the right coronary artery may improve accurate accessory pathway localization in these patients. 24 
Early and Late Electrophysiological Studies
Reciprocating tachycardia could not be induced in any patient during the early electrophysiological study. During follow-up, five patients had recurrence of accessory pathway conduction with symptomatic reciprocating tachycardia; all were reablated successfully. Although 41% of patients had intermittent palpitations during follow-up, these were described as being distinctly different from the episodes of tachycardia that they had before ablation. The late electrophysiological study was normal in 48 of 50 cases (96%). Two patients had anterograde preexcitation, but retrograde conduction over the accessory pathway was present in only one, who had inducible reciprocating tachycardia during an isoproterenol infusion. Both of these patients have been asymptomatic during 12 months of follow-up without antiarrhythmic drugs. Ventricular tachycardia could not be induced in any patient.
Discussion
This study demonstrates that a low-energy power source can be used safely and with a high success rate for selective ablation of accessory pathways in patients with the Wolff-Parkinson-White syndrome. High-energy DC ablation of accessory pathways was initially performed at the os of the coronary sinus for all patients with posteroseptal accessory pathways.3-5 Warin et a16-8 greatly expanded the technique of ablation of accessory pathways by directing the energy directly over the AV connection, and introduced the retrograde aortic approach for ablation of left free wall accessory pathways. However, the risk of serious complications such as sudden death,89 cardiac tamponade, coronary spasm, myocardial infarction, and heart block4-9 has limited the widespread acceptance of this procedure and has stimulated the search for safer techniques. The complications of high-energy DC ablation are mostly attributable to significant electrical arcing and barotrauma from a power source (a defibrillator) that was not designed for catheter ablation.1" '12,20 Low-Energy Direct-Current Power Source
In contrast, the low-energy power source used in this series produces tissue injury mediated by voltage or current density and largely avoids barotrauma. It can therefore be used with relative safety within the coronary sinus. 16 Test shocks of 2-10 J cause temporary disruption of conduction over the accessory pathway and are useful both for localizing the precise site for ablation and for evaluating the risk of heart block when accessory pathways are near the AV node. Repeated low-energy DC shocks of 15-30 J are then given to permanently ablate the accessory pathway.
The mean cumulative energy per patient in our series was 312±+284 J. This cumulative energy level reflects our learning curve, the limited lesion caused by the low-energy power source compared with high-energy DC ablation,7'16,26 and the difficulty in many patients to obtain close contact and stable positioning of the catheter used for ablation. However, the mean energy levels used for DC ablation of accessory pathways have been approximately 650 J,5,7 more than double the amount used in this study. Moreover, in our last 18 patients with left-sided accessory pathways, ablations have been successful with mean energy levels of less than 200 J.
Radiofrequency Energy
Radiofrequency energy causes tissue injury through resistive heating and usually avoids general anesthesia. 24 This new source of energy has been reported to be very safe and highly effective for ablation of accessory pathways, especially with the use of the large-tip electrode.21-23 However, prolonged procedure times have been reported,21 although only one ablation session was required in the majority of patients.2' 23 Table 1 summarizes the advantages and disadvantages of both lowenergy DC and radiofrequency. Coronary artery lesions have occasionally been reported (in vivo) with both power sources.16,27 None of the patients in our study (or in reports using radiofrequency)21-24 presented any subjective or objective findings suggestive of myocardial ischemia during follow-up.
Accessory Pathway Location
Previous surgical series have shown a difference in outcome of left free wall accessory pathways compared with other sites.28 In this report, procedure and fluoroscopy times were significantly related to accessory pathway location. Left-sided accessory pathways require less time for successful ablation, because the atrial or ventricular insertion of the accessory pathway is situated between the free wall and the mitral annulus.28-30 Transeptal or retrograde transaortic techniques allow precise positioning of the catheter close to the annulus. However, posteroseptal accessory pathways are located in a complex pyramidal space.31,32 For the electrophysiologist, the references used during fluoroscopy are the catheter located at the os of the coronary sinus and in the region of the His bundle; mapping may involve a relatively large area. An electrode catheter inserted into the right coronary artery may improve accurate mapping of right free wall accessory path- 
Conclusions
We have shown that low-energy DC can be used safely in children and adults for selective ablation of accessory pathways. The overall success rate was 92%, which was confirmed by late electrophysiological studies. Catheter ablation has become the treatment of choice for symptomatic patients with the Wolff-Parkinson-White syndrome. Future improvement in catheter design, mapping, and devices to deliver energy should result in greater accuracy of the technique and require less procedure and fluoroscopy times.
